Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1997-02-12
2000-04-18
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
A61K 3166
Patent
active
060515635
ABSTRACT:
The present invention provides methods of administering aminoalkyl phosphorothioate and/or aminoalkyl thiol compounds to patients in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.
REFERENCES:
patent: 3892824 (1975-07-01), Piper et al.
Betticher et al., 1995, "Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study," Br. J. Cancer 5:1551-1555.
Buntzel et al., 1996, "Selective Cytoprotection with Amifostine in Simultaneous Radiochemotherapy of Head Neck Cancer," Annals of Oncology 7 (Suppl.5):81(381P).
Buntzel et al., 1996, "Ethyol.RTM. (Amifostine) Provides Multilineage Hematoprotection and Protection Against Non-Hematologic Toxicities Induced by Radiochemotherapy (RCT) of Head and Neck Cancer," Blood 88(Suppl. 1):1781.
Constine et al., 1986, "Protection by WR-2721 of Human Bone Marrow Function Following Irradiation," Int. J. Radiation Oncology Biol. Phys. 12:1505-1508.
DiPaola et al., 1996, "A Phase I Study of Amifostine and Paclitaxel in Patients with Advanced Malignancies," Proceedings of ASCO 15:488(1156).
Dorr et al., 1995, "Selective Cardioprotection of Rat Heart Myocytes Exposed to DNA Intercalating Agents Using Amifostine (AMI) and its Dephosphorylated Metabolite, WR-1065," Eur. J. Cancer 31A(Suppl. 5):S123(579).
Glover et al., 1986, "WR-2721 Protects Against the Hematologic Toxicity of Cyclophosphamide: A Controlled Phase II Trial," J. Clin. Oncol. 4:584-588.
Kemp et al., 1996, "Amifostine Pretreatment for Protection Against Cyclophosphamide-Induced and Cisplatin-Induced Toxicities: Results of a Randomized Control Trail in Patients with Advanced Ovarian Cancer," J. Clin. Oncol. 14:2101-2112.
List et al., 1996, "Amifostine Promotes Multilineage Hematopoiesis in Patients with Myelodysplastic Syndrome (MDS): Results of a Phase I/II Clinical Trial," Blood 88(10) Suppl 1:453a(1802) (abstract).
List et al., 1996, "Amifostine Stimulates Formation of Multipotent Progenitors and Generates Macroscopic Colonies in Normal and Myelodysplastic Bone Marrow," Proceedings of ASCO 15:449(1403).
List et al., 1996, "Amifostine Protects Primitive Hematopoietic Progenitors Against Chemotherapy Cytotoxicity," Seminars in Oncology 23(4)Suppl. 8:58-63.
Liu et al., 1992, "Use of Radiation With or Without WR-2721 in Advanced Rectal Cancer," Cancer 69:2820-2825.
McDonald et al., 1994, "Preliminary Results of a Pilot Study Using WR-2721 Before Fractionated Irradiation of the Head and Neck to Reduce Salivary Gland Dysfunction," Int. J. Radiation Oncology Biol. Phys. 29:747-754.
McDonald et al., 1995, "Amifostine Preserves the Salivary Gland Function During Irradiation of the Head and Neck," European Journal of Cancer 31A(Suppl. 5):415.
Phillips and Wasserman, 1984, "Promise of Radiosensitizers and Radioprotectors in the Treatment of Human Cancer," Cancer Treat. Rep. 68:291-302.
Schiller et al., 1996, "Amifostine, Cisplatin, and Vinblastine in Metastatic Non-Small-Cell Lung Cancer: A Report of High Response Rates and Prolonged Survival," J. Clin. Oncol. 14(6):1913-1921.
Shaw et al., 1986, "Human Pharmacokinetics of WR-2721," Int. J. Radiation Oncology Biol. Phys. 12:1501-1504.
Shaw et al., 1988, "Pharmacokinetics of WR-2721," Pharmac. Ther. 39:195-201.
Shaw et al., 1994, "Pharmacokinetics of Amifostine in Cancer Patients: Evidence for Saturable Metabolism." Proceedings of ASCO 13:144(371).
Tabachnik et al. 1980, "Studies on the Reduction of Sputum Viscosity in Cystic Fibrosis Using an Orally Absorbed Protected Thiol," J. Pharmacol. Exp. Ther. 214:246-249.
Tabachnik et al. 1982, "Protein Binding of N-2-Mercaptoethyl-1, 3-Diaminopropane via Mixed Disulfide Formation after Oral Administration of WR 2721," J. Pharmacol. Exp. Ther. 220:243-246.
Wadler et al., 1993, "Pilot Trial of Cisplatin, Radiation, and WR2721 in Carcinoma of the Uterine Cervix: A New York Gynecologic Oncology Group Study," J. Clin. Oncol. 11:1511-1516.
Wasserman et al., 1981, "Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721," Cancer Clin. Trials 4:3-6.
Yuhas, 1973, "Radiotherapy of Experimental Lung Tumors in the Presence and Absence of a Radioprotective Drug, S-2-(3-aminopropylamino)ethylphosphorothioic Acid (WR-2721)," J. Natl. Cancer. Inst. 50:69-78.
Schein Philip S.
Stogniew Martin
Goldberg Jerome D.
U.S. Bioscience, Inc.
LandOfFree
Methods for the administration of amifostine and related compoun does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the administration of amifostine and related compoun, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the administration of amifostine and related compoun will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2336477